Cyclosporine for acute encephalopathy with biphasic seizures and late reduced diffusion

Pediatrics International

Volumn 56, Issue 4, 2014, Pages 577-582

  Watanabe, Yoshihiro ^a   Motoi, Hirotaka ^a   Oyama, Yoshitaka ^a   Ichikawa, Kazushi ^a   Takeshita, Saoko ^a   Mori, Masaaki ^a   Nezu, Atsuo ^a   Yokota, Shumpei ^b  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Acute encephalopathy with biphasic seizures and late reduced diffusion; Cyclosporine; Encephalopathy; Status epilepticus; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYCLOSPORIN; METHYLPREDNISOLONE; NORPHENAZONE; IMMUNOSUPPRESSIVE AGENT;

ACUTE BRAIN DISEASE; ACUTE ENCEPHALOPATHY WITH BIPHASIC SEIZURE AND LATE REDUCED DIFFUSION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION; DRUG EFFICACY; EPSTEIN BARR VIRUS INFECTION; FEMALE; FRONTAL LOBE; HEMISPHERE; HERPES SIMPLEX; HUMAN; HYPERTENSION; INFANT; INFLUENZA; MALE; NEUROIMAGING; NEUROLOGIC DISEASE ASSESSMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDIATRIC CEREBRAL PERFORMANCE CATEGORY SCALE; PEDIATRIC OVERALL PERFORMANCE CATEGORY SCALE; PRIORITY JOURNAL; PROGNOSIS; PROGNOSTIC ASSESSMENT; RETROSPECTIVE STUDY; SEIZURE; TREATMENT OUTCOME; ACUTE DISEASE; BRAIN DISEASES; PRESCHOOL CHILD; SEIZURES; SYNDROME;

ACUTE DISEASE; BRAIN DISEASES; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; RETROSPECTIVE STUDIES; SEIZURES; SYNDROME;

EID: 84926208911     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/ped.12288     Document Type: Article

References (31)

1. Takanashi J, Oba H, Barkovich AJ et al. Diffusion MRI abnormalities after prolonged febrile seizures with encephalopathy. Neurology 2006; 66: 1304-9.
2. Takanashi J. Two newly proposed infectious encephalitis/encephalopathy syndromes. Brain Dev. 2009; 31: 521-8.
3. Mizuguchi M, Yamanouchi H, Ichiyama T., Shiomi M. Acute encephalopathy associated with influenza and other viral infections. Acta Neurol. Scand. 2007; 115: 45-56.
4. Hoshino A, Saitoh M, Oka A et al. Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes. Brain Dev. 2012; 34: 337-43.
5. Morishima T, Okabe N, Nakamura Y et al. Guideline revised edition for the management of influenza associated encephalopathy (in Japanese). J. Pediatr. Infect. Dis. Immunol. (Tokyo) 2010; 21: 421-66.
6. Kahan BD. Cyclosporine. N. Engl. J. Med. 1989; 321: 1725-38.
7. Yamanouchi H, Kawaguchi N, Mori M et al. Acute infantile encephalopathy predominantly affecting the frontal lobes. Pediatr. Neurol. 2006; 34: 93-100.
8. Yamanouchi H, Mizuguchi M. Acute infantile encephalopathy predominantly affecting the frontal lobes (AIEF): A novel clinical category and its tentative diagnostic criteria. Epilepsy Res. 2006; 70: S263-268.
9. Gastaut H, Poirier F, Payan H., Salamon G, Toga M. H.H.E.syndrome; hemiconvulsions, hemiplegia, epilepsy. Epilepsia 1960; 1: 418-47.
10. Fiser DH. Assessing the outcome of pediatric intensive care. J. Pediatr. 1992; 121: 68-74.
11. Takanashi J, Tada H, Terada H., Barkovich AJ. Excitotoxicity in acute encephalopathy with biphasic seizures and late reduced diffusion. AJNR Am. J. Neuroradiol. 2009; 30: 132-5.
12. Tadokoro R, Okumura A, Nakazawa T et al. Acute encephalopathy with biphasic seizures and late reduced diffusion associated with hemophagocytic syndrome. Brain Dev. 2010; 32: 477-81.
13. Tanuma N, Miyata R, Kumada S et al. The axonal damage marker tau protein in the cerebrospinal fluid is increased in patients with acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev. 2010; 32: 435-9.
14. Ichiyama T, Suenaga N, Kajimoto M et al. Serum and CSF levels of cytokines in acute encephalopathy following prolonged febrile seizures. Brain Dev. 2008; 30: 47-52.
15. Hayashi N, Okumura A, Kubota T et al. Prognostic factors in acute encephalopathy with reduced subcortical diffusion. Brain Dev. 2012; 34: 632-9.
16. Gunn AJ, Thoresen M. Hypothermic neuroprotection. NeuroRx 2006; 3: 154-69.
17. Polderman KH. Induced hypothermia and fever control for prevention and treatment of neurological injuries. Lancet 2008; 371: 1955-69.
18. Kawano G, Iwata O, Iwata S et al. Determinants of outcomes following acute child encephalopathy and encephalitis: Pivotal effect of early and delayed cooling. Arch. Dis. Child. 2011; 96: 936-41.
19. Nakagawa T, Fujita K, Saji Y., Maruyama A, Nagase H. Induced hypothermia/normothermia with general anesthesia prevents neurological damage in febrile refractory status epilepticus in children. No to Hattatsu (Tokyo) 2011; 43: 459-63 (in Japanese).
20. Hui KK, Liadis N, Robertson J., Kanungo A, Henderson JT. Calcineurin inhibition enhances motor neuron survival following injury. J. Cell. Mol. Med. 2010; 14: 671-86.
21. Snyder SH, Sabatini DM, Lai M.M., Steiner JP, Hamilton GS, Suzdak PD. Neural actions of immunophilin ligands. Trends Pharmacol. Sci. 1998; 19: 21-6.
22. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: A review. J. Neurol. 1999; 246: 339-46.
23. Bradham CA, Qian T, Streetz K., Trautwein C, Brenner DA, Lemasters JJ. The mitochondrial permeability transition is required for tumor necrosis factor alpha-mediated apoptosis and cytochrome c release. Mol. Cell. Biol. 1998; 18: 6353-64.
24. Yokota S, Imagawa T, Miyamae T et al. Hypothetical pathophysi-ology of acute encephalopathy and encephalitis related to influenza virus infection and hypothermia therapy. Pediatr. Int. 2000; 42: 197-203.
25. Uchino H, Ishii N, Shibasaki F. Calcineurin and cyclophilin D are differential targets of neuroprotection by immunosuppressants CsA and FK506 in ischemic brain damage. Acta Neurochir. Suppl. 2003; 86: 105-11.
26. Matsuo M, Maeda T, Ono N et al. Efficacy of dextromethorphan and cyclosporine A for acute encephalopathy. Pediatr. Neurol. 2013; 48: 200-5.
27. de Groen PC. Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin. Proc. 1988; 63: 1012-21.
28. de Groen PC. Cyclosporine: Review and its specific use in liver transplantation. Mayo Clin. Proc. 1989; 64: 680-89.
29. Walker RW, Brochstein JA. Neurologic complications of immuno-suppressive agents. Neurol. Clin. 1988; 6: 261-78.
30. Mirsattari SM, Wilde NJ, Pigott SE. Long-term cognitive outcome of hemiconvulsion-hemiplegia-epilepsy syndrome affecting the left cerebral hemisphere. Epilepsy Behav. 2008; 13: 678-80.
31. Tenney JR, Scapiro MB. Child neurology: Hemiconvulsion-hemiplegia-epilepsy syndrome. Neurology 2012; 79: e1-4.